



NGO "Adults with ADHD"

A light of hope for everyone with ADHD, let's unite in the fight!


Age and age of diagnosis




Reasons for not having a prescription




Types of treatment that have been used




Evaluation of treatment






Age and age of diagnosis




Types of treatment that have been used




Evaluation of treatment




Types of treatment that have been used




Age




Treatment the child receives



Types of treatment that have been used



Evaluation of treatment




Gaps in current treatment:

- lack of highly qualified specialists
- systematic problems in the medical structure
- lack of access to specific treatment methods (Concerta, Vyvanse)


Expectations:

- improvement of living standards
- improvement of concentration
- reduction of ADHD symptoms

The majority of respondents live in **Kyiv (399)**, **Lviv (107)** and **Kharkiv (62)** regions. The level of participation in the survey varies from region to region.



Status



- An adult with ADHD but without a prescription for stimulants
- An adult with ADHD and a prescription for stimulants
- Mother/father of a child with ADHD
- Adult with suspected ADHD, TRUE
- Adult with suspected ADHD, FALSE

The survey included 4 categories of respondents:

- Adult with ADHD but no prescription for stimulants - 154
- Adult with ADHD and a prescription for stimulants - 55
- Mother/father of a child with ADHD - 90
- Adult with suspected ADHD 709.

Confirmed ADHD: 681 (96%).

Conclusion: Awareness of ADHD symptoms is high.


Age: 18-25 is the most active group .

Diagnosis: Peak at 18-25, most at 18-30.


Conclusion: ADHD symptoms become more noticeable/impactful at a younger age.

Possible reasons: Transition to higher education, the beginning of a career, need for organization.

Age and age of diagnosis



Type of treatment in a child



Methods: Medications (stimulants, non-stimulants), psychotherapy (CBT, DBT, skill development courses).


Psychotherapy: Skills development, behavioral improvement, academic performance.

When we analyze these reasons why adults with ADHD do not have a prescription for stimulants, we can understand the different barriers and preferences that exist in this group.

Recommendations:

- Alternative treatment methods
- Improving access to specialists
- Educational campaigns
- Monitoring of the condition
- Respect for patients' choices

Reasons for not having a prescription



Methods for the management of ADHD


The most common method: Psychotherapy 395

Medications:


Stimulants: 113

Non-stimulants: 119

Not treated: 508



Possible reasons: Lack of need/access.



Quality of life: Improves during treatment.

Effectiveness: Mostly positive, but there are exceptions.

Conclusion: Comprehensive treatment strategies are needed.

Raising Awareness and Education

Problems: Insufficient awareness of ADHD among the public and healthcare professionals.

Solution options: Development of information campaigns, training programs for healthcare professionals, integration of ADHD into school curricula.

Benefits for the pharmaceutical company: Increased demand for medicines, improved reputation of the company as a socially responsible business.

Development of Infrastructure for Non-pharmacological Treatment

Issue: Limited access to non-pharmacological treatments such as psychotherapy or skills training.

Solution options: Create support centers, secure funding to expand existing programs.

Benefits for the pharmaceutical company: Market expansion through the introduction of products for non-pharmaceutical treatment.

Ensuring Wider Access to Medicines

Problem: The Ukrainian market has only one first-line treatment for ADHD with significant supply problems and one second-line drug that has a high price. This creates serious barriers for patients' access to adequate treatment.

Solution options: Expanding the List of Available Medicines; Lobbying for Regulatory Changes; Cooperation with Manufacturers.

Benefits for the pharmaceutical company: Increasing the market for new drugs, strengthening market positions, enhancing reputation due to social responsibility and contribution to improving public health.

Improving the Support System

Problem: Insufficient support for patients and their families after diagnosis.

Solution options: Development of public organizations, creation of an online support platform, introduction of hotlines.

Benefits for the pharmaceutical company: Increased customer loyalty, opportunity to participate in social programs.